l‐carnitine downregulate the muscle wasting effect of glucocorticoids in pemphigus patient: A randomized double‐blind placebo‐controlled study

Pemphigus Vulgaris (PV) is a blistering autoimmune disease caused by autoantibodies against desmoglein 1 and 3. Treatment options are limited to corticosteroids and immunosuppressants. The myotoxic effect of glucocorticoids is a fact that has been elucidated. So, the development of efficacious treatment approaches to combat muscle wasting is of great importance. Considering the adverse effect of glucocorticoid therapy in pemphigus patients and altered muscle metabolism, this study aimed to investigate the effect of l‐carnitine supplementation which can be useful in combating muscle‐wasting impact of glucocorticoid therapy. In this randomized double‐blind placebo‐controlled trial 44 pemphigus patients aged from 30 to 65 years, receiving glucocorticoid therapy were selected to evaluate the suitability of l‐carnitine (LC) as an anti‐wasting substance. Patients were randomly divided into two groups to receive 2 g/d l‐carnitine or placebo for 8 weeks; serum markers of muscle metabolism (IGF‐1, creatine kinase, myogenin, myostatin) was evaluated before and after the l‐carnitine supplementation. Paired T‐test was used to analyze the differences between variables before and after the intervention. Therefore, the student's t‐test was performed to find any differences in baseline characteristics and dietary intakes between the trial groups. LC intake led to a significant rise in serum IGF‐1 and a reduction in CK and myostatin levels compared to baseline (p